Cardiomyopathy Medication Market Research Report - Global Forecast till 2027

Global Cardiomyopathy Medication Market Research Report: By Type (Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Unclassified Cardiomyopathy), By Treatment (Anticoagulants, Antiarrhythmics, Anti-Hypertensives, Cardiac Glycosides, Diuretics) and By End User (Homecare, Hospitals and Clinics, Others) – Forecast to 2027

ID: MRFR/HC/6784-HCR | February, 2021 | Region : Global

Market Forecast


Global Cardiomyopathy Medication Market is expected to grow from USD 562.4 Million in 2018 to USD 620 Million by 2025 at a CAGR of 4.6%.


Cardiomyopathy medication is extensively used in North America and Europe and is fast becoming mainstream in Asia-Pacific.


A growing geriatric population and changing lifestyle habits are contributing to the increased incidence of cardiomyopathy. It is the third major cause of heart failure in the US and affects five in 100,000 adults in the country.


Market USP


Increase in number of cardiomyopathy cases and need for lifelong medication to manage the condition.


Market Drivers



  • Increased prevalence of hypertension, congenital heart abnormalities, and valve disease.

  • Rising incidence rate among the growing geriatric population .

  • Changes in lifestyle.

  • Lifelong medication required to manage the condition.

  • Preferred alternative to surgery

  • Recent product launches for treatment of hereditary transthyretin-mediated amyloidosis ATTR-CM. For instance, in May 2019, the US Food and Drug Administration (FDA) approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of ATTR-CM.


Market Restraints



  • High costs of cardiomyopathy treatment. The cost can be as high as USD 225,000 per annum per person for uninsured patients.

  • Availability of alternative therapies and surgical options.


SEGMENTATION


By Type



  • Dilated Cardiomyopathy: The largest segment the causes of dilated cardiomyopathy vary from infections to genetic and birth disorders. As of June 2019, an estimated 750,000 people suffered from dilated cardiomyopathy in the US which contributes to the largest share of this segment. A large section of the geriatric population also has dilated cardiomyopathy, requiring prolonged use of medication, thereby driving market growth. 



  • Hypertrophic Cardiomyopathy: The fastest-growing segment. The growth of the segment is driven by the increasing prevalence of diabetes and thyroid diseases across the globe, which are the two main factors for this type of cardiomyopathy.



  • Restrictive Cardiomyopathy: Weakening of the valves and valve damage cause restrictive cardiomyopathy. It is crucial to manage this condition with medication to avoid expensive surgeries. This segment shows growth potential due to the critical nature of the condition.



  • Arrhythmogenic Right Ventricular Dysplasia: A relatively rare disorder affecting teens and young adults due to the formation of scar tissue and fatty deposits on the heart muscles; it is one of the leading causes of sudden cardiac arrests in the young section of the population. Lifelong medication is required to manage this condition, which is a driver for the growth of the segment.



  • Unclassified Cardiomyopathy: Cardiomyopathy due to other causes, is a niche market segment.


By Treatment



  • Anticoagulants: This type of medication is used widely for the treatment of cardiomyopathy.



  • Antiarrhythmics: This medication is used primarily for the treatment of hypertrophic cardiomyopathy.



  • Anti-Hypertensives: Used in conjunction with other drugs to treat cardiomyopathy, this medication is useful in regulating blood pressure. The segment holds the largest market share, by treatment, owing to the widespread use of anti-hypertensives in the treatment of all types of cardiomyopathy.



  • Cardiac Glycosides: These drugs strengthen the heart’s ability to pump blood by acting on the cellular sodium-potassium ATPase pump. Very useful for treating cardiomyopathy, especially arrhythmogenic right ventricular dysplasia.



  • Diuretics: Excellent for the treatment of restrictive cardiomyopathy, diuretics help in expelling excess water and salts from the body.


By End User



  • Homecare: The fastest-growing segment due to the chronic nature of cardiomyopathy and the increasing number of elderly individuals who receive care at home. The growth of the segment can also be attributed to reduced treatment costs as well as the increasing access to medication.



  • Hospitals and Clinics: The largest segment, hospitals and clinics are still the primary points for the distribution of cardiomyopathy medication. The presence of several hospitals dedicated to cardiology is another factor driving the growth of the segment.



By Region



  • Americas: Presently the largest regional market, the prevalence of cardiomyopathy is increasing in the Americas due to a combination of a growing geriatric population, genetics, and environmental factors. Additionally, rising domestic treatment rates backed by reimbursement for drugs in the US are driving market growth in the region.



  • Europe: An emphasis on healthy lifestyles and careful medical monitoring ensure fewer cases of cardiomyopathy in Europe as compared to the Americas. However, the prevalence of the disease is rising in the region due to the presence of a large geriatric population.



  • Asia-Pacific: The fastest-growing regional market owing to the increasing prevalence of conditions that lead to cardiomyopathy such as hypertension and congenital heart disorders. Expansion of cardiomyopathy medication manufacturers in the region and frequent product launches are likely to bolster market growth in the coming years.



  • Middle East & Africa: The population in the Middle East & Africa is genetically predisposed to heart disease, including cardiomyopathy, which is driving the growth of the market.


Key Players



  • Pfizer Inc.

  • PhaseBio Pharmaceuticals, Inc.

  • Array Biopharma, Inc.

  • AstraZeneca

  • Sanofi-Aventis US LLC

  • Hoffmann-La Roche Ltd

  • Merck & Co., Inc.

  • Capricor Therapeutics

  • MyoKardia

  • Janssen Products, LP

  • Ionis Pharmaceuticals, Inc.

  • Medtronic

  • Becton And Dickson & Co.

  • Biomerieux

  • Teva Pharmaceutical Industries Ltd

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Cardiomyopathy Medication Market, by Type

6.1 Introduction

6.2 Dilated Cardiomyopathy

6.3 Hypertrophic Cardiomyopathy

6.4 Restrictive Cardiomyopathy

6.5 Arrhythmogenic Right Ventricular Dysplasia

6.6 Unclassified Cardiomyopathy

Chapter 7. Global Cardiomyopathy Medication Market, by Treatment

7.1 Introduction

7.2 Anticoagulants

7.3 Antiarrhythmics

7.4 Anti-Hypertensives

7.4.1 ACE Inhibitors

7.4.2 Angiotensin II Receptor Blockers

7.4.3 Beta Blockers

7.4.4 Calcium Channel Blockers

7.5 Cardiac Glycosides

7.6 Diuretics

Chapter 8. Global Cardiomyopathy Medication Market, by End User

8.1 Introduction

8.2 Homecare

8.3 Hospitals & Clinics

8.4 Others

Chapter 9. Global Cardiomyopathy Medication Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 UAE

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Competitive Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Developments & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer Inc.

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products/Services Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2 PhaseBio Pharmaceuticals, Inc.

11.2.1 Company Overview

11.2.2 Financial Overview

11.2.3 Products/Services Offered

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 Array Biopharma, Inc.

11.3.1 Company Overview

11.3.2 Financial Overview

11.3.3 Products/Services Offered

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.3.6 Key Strategies

11.4 AstraZeneca

11.4.1 Company Overview

11.4.2 Financial Overview

11.4.3 Products/Services Offered

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.6 Key Strategies

11.5 Sanofi-Aventis US LLC

11.5.1 Company Overview

11.5.2 Financial Overview

11.5.3 Products/Services Offered

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategies

11.6 F. Hoffmann-La Roche Ltd

11.6.1 Company Overview

11.6.2 Financial Overview

11.6.3 Products/Services Offered

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Merck & Co., Inc.

11.7.1 Company Overview

11.7.2 Financial Overview

11.7.3 Products/Services Offered

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 Capricor Therapeutics

11.8.1 Company Overview

11.8.2 Financial Overview

11.8.3 Products/Services Offered

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 MyoKardia

11.9.1 Company Overview

11.9.2 Financial Overview

11.9.3 Products/Services Offered

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 Janssen Products, LP

11.10.1 Company Overview

11.10.2 Financial Overview

11.10.3 Products/Services Offered

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 Ionis Pharmaceuticals, Inc.

11.11.1 Company Overview

11.11.2 Financial Overview

11.11.3 Products/Services Offered

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.6 Key Strategies

11.12 Medtronic

11.12.1 Company Overview

11.12.2 Financial Overview

11.12.3 Products/Services Offered

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

11.13 Becton And Dickson & Co.

11.13.1 Company Overview

11.13.2 Financial Overview

11.13.3 Products/Services Offered

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.13.6 Key Strategies

11.14 Biomerieux

11.14.1 Company Overview

11.14.2 Financial Overview

11.14.3 Products/Services Offered

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.14.6 Key Strategies

11.15 Teva Pharmaceutical Industries Ltd

11.15.1 Company Overview

11.15.2 Financial Overview

11.15.3 Products/Services Offered

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.15.6 Key Strategies

11.16 Others

Chapter 13. Appendix

13.1. References

13.2. Related Reports

LIST OF TABLES

Table 1 Global Cardiomyopathy Medication Synopsis, 2020-2027

Table 2 Global Cardiomyopathy Medication Market Estimates & Forecast, 2020-2027(USD Million)

Table 3 Global Cardiomyopathy Medication Market, by Region, 2020-2027(USD Million)

Table 4 Global Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 5 Global Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 6 Global Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 7 Americas: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 8 Americas: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 9 Americas: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 10 Americas: Cardiomyopathy Medication Market, by Region, 2020-2027(USD Million)

Table 11 North America: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 12 North America: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 13 North America: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 14 Latin America: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 15 Latin America: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 16 Latin America: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 17 Europe: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 18 Europe: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 19 Europe: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 20 Europe: Cardiomyopathy Medication Market, by Region, 2020-2027(USD Million)

Table 21 Western Europe: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 22 Western Europe: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 22 Western Europe: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 23 Eastern Europe: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 24 Eastern Europe: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 25 Eastern Europe: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 26 Asia-Pacific: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 27 Asia-Pacific: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 28 Asia-Pacific: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

Table 29 Middle East & Africa: Cardiomyopathy Medication Market, by Type, 2020-2027(USD Million)

Table 30 Middle East & Africa: Cardiomyopathy Medication Market, by Treatment, 2020-2027(USD Million)

Table 31 Middle East & Africa: Cardiomyopathy Medication Market, by End User, 2020-2027(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Global Cardiomyopathy Medication Market

Figure 3 Market Dynamics for the Global Cardiomyopathy Medication Market

Figure 4 Global Cardiomyopathy Medication Market Share, by Type, 2020

Figure 5 Global Cardiomyopathy Medication Market Share, by Treatment, 2020

Figure 6 Global Cardiomyopathy Medication Market Share, by End User, 2020

Figure 7 Global Cardiomyopathy Medication Market Share, by Region, 2020

Figure 8 Americas: Cardiomyopathy Medication Market Share, by Region, 2020

Figure 9 North America: Cardiomyopathy Medication Market Share, by Country, 2020

Figure 10 Europe: Cardiomyopathy Medication Market Share, by Country, 2020

Figure 11 Western Europe: Cardiomyopathy Medication Market Share, by Country, 2020

Figure 12 Asia-Pacific: Cardiomyopathy Medication Market Share, by Country, 2020

Figure 13 Middle East & Africa: Cardiomyopathy Medication Market Share, by Country, 2020

Figure 14 Global Cardiomyopathy Medication Market: Company Share Analysis, 2020 (%)

Figure 15 Pfizer Inc.: Key Financials

Figure 16 Pfizer Inc.: Segmental Revenue

Figure 17 Pfizer Inc.: Regional Revenue

Figure 18 PhaseBio Pharmaceuticals, Inc.: Key Financials

Figure 19 PhaseBio Pharmaceuticals, Inc.: Segmental Revenue

Figure 20 PhaseBio Pharmaceuticals, Inc.: Regional Revenue

Figure 21 Array Biopharma, Inc.: Key Financials

Figure 22 Array Biopharma, Inc.: Segmental Revenue

Figure 23 Array Biopharma, Inc.: Regional Revenue

Figure 24 AstraZeneca: Key Financials

Figure 25 AstraZeneca: Segmental Revenue

Figure 26 AstraZeneca: Regional Revenue

Figure 27 Sanofi-Aventis US LLC: Key Financials

Figure 28 Sanofi-Aventis US LLC: Segmental Revenue

Figure 29 Sanofi-Aventis US LLC: Regional Revenue

Figure 30 F. Hoffmann-La Roche Ltd: Key Financials

Figure 31 F. Hoffmann-La Roche Ltd: Regional Revenue

Figure 32 F. Hoffmann-La Roche Ltd: Key Financials

Figure 33 Merck & Co., Inc.: Segmental Revenue

Figure 34 Merck & Co., Inc.: Regional Revenue

Figure 35 Merck & Co., Inc.: Key Financials

Figure 36 Capricor Therapeutics: Segmental Revenue

Figure 37 Capricor Therapeutics: Regional Revenue

Figure 38 Capricor Therapeutics: Key Financials

Figure 39 MyoKardia: Segmental Revenue

Figure 40 MyoKardia: Regional Revenue

Figure 41 MyoKardia: Key Financials

Figure 42 Janssen Products, LP: Segmental Revenue

Figure 43 Janssen Products, LP: Regional Revenue

Figure 44 Janssen Products, LP: Key Financials

Figure 45 Ionis Pharmaceuticals, Inc.: Segmental Revenue

Figure 46 Ionis Pharmaceuticals, Inc.: Regional Revenue

Figure 47 Ionis Pharmaceuticals, Inc.: Key Financials

Figure 48 Medtronic: Segmental Revenue

Figure 49 Medtronic: Regional Revenue

Figure 50 Medtronic: Key Financials

Figure 51 Becton And Dickson & Co.: Segmental Revenue

Figure 52 Becton And Dickson & Co.: Regional Revenue

Figure 53 Becton And Dickson & Co.: Key Financials

Figure 54 Biomerieux: Segmental Revenue

Figure 55 Biomerieux: Regional Revenue

Figure 56 Biomerieux: Key Financials

Figure 57 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 58 Teva Pharmaceutical Industries Ltd: Regional Revenue

Figure 59 Teva Pharmaceutical Industries Ltd: Key Financial



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.